Buy Before Midterms, Exit Post-Election: A Tactical 3-Stock Play

The core event is clear: midterm elections are just three weeks away. Historically, the market's reaction to the post-election period has been powerful. The S&P 500 has risen 17% in the 12 months following midterm elections since 1932, with positive returns in 21 of the last 22 such years. This sets up a defined tactical window-buy before the vote for the clarity it brings, exit after the initial tailwind fades.

The mechanism is straightforward. Political uncertainty typically peaks during the campaign, creating a headwind for risk assets. Once the dust settles and the new legislative landscape is known, that uncertainty lifts. This historically spells good news for equity markets, with the strongest gains often occurring 6 to 12 months after the vote. The market rewards the policy clarity that follows.

The current context, however, introduces a twist. This year's elections are less of a market concern than usual. Dominant macro factors like inflation, monetary policy, and geopolitics are now the primary drivers, according to Goldman Sachs. This could mean pre-election volatility is muted. For a tactical investor, that's a double-edged sword. It reduces the risk of a sharp pre-election sell-off, but it also suggests the post-election "tailwind" might be weaker or more muted than in past cycles. The historical return remains a useful benchmark, but its magnitude may be tempered by today's broader economic backdrop.

Stock 1: Eli Lilly (LLY) - The Weight Management Growth Engine

The catalyst here is a blockbuster drug in its prime. Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, is the world's best-selling medicine, with revenue of $24.8 billion through the first nine months of 2025. This isn't a near-term blip; it's a sustained growth engine that has already reshaped the pharmaceutical landscape.

The growth trajectory is secured by a formidable pipeline. While competition from Novo Nordisk and others is rising, Lilly's clinical data is superior. Its oral weight-loss candidate, orforglipron, recently completed phase 3 trials and could receive a regulatory decision by the end of February. More importantly, its next-generation drug, retatrutide, delivered a mean weight loss of 28.7% at the highest dose in a phase 3 study-performance that industry analysts say is unmatched. This pipeline depth is a direct moat against rivals.

That leads to the valuation argument. Yes, the stock trades at a premium, with a forward P/E of 33 times earnings versus a sector average of 18.2. But the PEG ratio tells a different story. With a price/earnings-to-growth of only 0.98, the market is pricing in a growth rate that justifies the multiple. In other words, the stock is not overvalued relative to its own explosive earnings expansion.

For a tactical play, Lilly represents a core holding because its catalyst is visible and measurable. The weight management market is still expanding, and Lilly's franchise is the clear leader. The post-election clarity could further de-risk the biotech sector, potentially benefiting a stock like this that is fundamentally sound. The setup is simple: a dominant product, a deep pipeline, and a valuation that reflects its growth, not a fantasy.

Stock 2: UnitedHealth Group (UNH) - The Turnaround Play

The catalyst here is a clear, aggressive operational reset. UnitedHealth Group is systematically exiting its least profitable Medicare Advantage markets and focusing on premium increases in its remaining, higher-quality segments. This is a direct response to pressure from regulators and a desire to improve its core profitability. The move is a classic turnaround play: trimming low-margin business to boost returns on the rest.

That operational shift has a defensive edge that matters. Unlike a bank, UnitedHealth's core insurance model doesn't rely on lending. It collects premiums and pays claims, avoiding the need to set aside capital for loan losses. This structural difference means the company is less vulnerable to economic downturns and can bounce back faster when the economy stabilizes. In a post-election environment where policy clarity could ease regulatory overhang, this defensive profile becomes a tangible advantage.

The sector context amplifies the opportunity. The healthcare sector is gaining momentum, with investors rotating out of tech-heavy portfolios. As noted, health care stocks are gaining momentum due to increased investment inflows, and the sector has a history of outperforming in midterm election years. This creates a favorable backdrop for a stock like UNH, where the catalyst is a specific, near-term operational improvement within a sector that is already in favor.

The setup is tactical: a defensive stock with a clear turnaround plan, trading within a sector that is already seeing positive sentiment and momentum. The post-election clarity could remove a key overhang, allowing the market to reward the company's strategic focus.

Stock 3: Visa (V) - The Defensive Tech Play

The third leg of this tactical trio is a tech stock with a defensive core. Visa (V) operates on a fundamentally different model than traditional lenders. By focusing solely on payment facilitation and avoiding lending, it sidesteps the need to set aside capital for loan losses. This structural advantage means the company is less vulnerable to economic downturns and can bounce back faster when the economy stabilizes. In a post-election environment where policy clarity could ease regulatory overhang, this defensive profile becomes a tangible advantage.

Performance history underscores its resilience. Shares have climbed in 13 of the last 15 years, with only two minor declines in 2021 and 2022. That track record of consistent, positive returns makes it a reliable anchor in a portfolio, especially when paired with more volatile healthcare names.

More importantly, Visa's momentum can serve as a leading signal. Its strong performance often reflects a broader rotation into consumer-facing and tech sectors. This is evident in the recent moves of major ETFs; the Vanguard Information Technology Index Fund (VGT) and health care ETFs have both gained momentum, mirroring Visa's own climb. When Visa rallies, it often signals that investor money is flowing into these growth-oriented areas, betting on sustained consumer spending and digital adoption.

For this play, Visa provides the diversification and momentum-fueled defensive layer. It's a stock that benefits from the same post-election clarity that helps healthcare, but through a different lens-one of resilient, fee-based revenue and sector rotation. It's the tactical counterbalance to the biotech and insurance names, rounding out a thesis built on clarity, growth, and defensive positioning.

Execution: Catalysts, Risks, and Exit Timing

The tactical setup is clear: buy before the election for the post-election tailwind, exit as the 12-month catalyst nears. But execution requires monitoring specific signals and managing defined risks.

First, the leading indicators. Watch the Vanguard Information Technology Index Fund (VGT) and health care ETFs like the SPDR Health Care Select Sector ETF (XLV). Their momentum is a direct read on the sector rotation driving this play. As noted, health care stocks are gaining momentum due to increased investment inflows, with XLV up nearly 9% in four weeks as of Thanksgiving. When these ETFs climb, it confirms the rotation into consumer-facing and tech sectors is real. A stall or reversal in their performance would be an early warning that the broader market momentum supporting this trio is fading, signaling it's time to reassess.

Second, the key risks. The macro environment is the primary overhang. Inflation and monetary policy are now the dominant drivers, overshadowing the election effect. If data shows persistent inflation or a hawkish Fed shift, it could quickly dampen the post-election optimism for all three stocks. For the healthcare names, an unexpected regulatory shift is a specific sector risk. Any new policy that pressures Medicare Advantage margins or drug pricing could directly impact UnitedHealth and Eli Lilly, negating their operational improvements.

Finally, the exit timing. The historical playbook is our guide. The S&P 500 has risen 17% in the 12 months following midterm elections since 1932. The strongest gains typically occur within that window. Therefore, the tactical exit should be as the 12-month period from the election approaches its end. This isn't a rigid date, but a framework: monitor the sector ETFs for signs of exhaustion, watch for macro data that shifts the risk/reward, and plan to exit as the post-election clarity fades and the next cycle begins. The goal is to capture the defined tailwind, not to hold through the next uncertainty.